| [1] |
SIEGEL R L, KRATZER T B, GIAQUINTO A N, et al. Cancer statistics,2025[J]. CA Cancer J Clin, 2025, 75(1):10-45. doi:10.3322/caac.21871.
|
| [2] |
SUN L, HE M, LIU D, et al. Deacetylation of ANXA2 by SIRT2 desensitizes hepatocellular carcinoma cells to donafenib via promoting protective autophagy[J]. Cell Death Differ, 2025, 32(9):1630-1647. doi:10.1038/s41418-025-01499-3.
|
| [3] |
ZHANG G P, SONG Z B, CHEN D H, et al. Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma[J]. Oncogene, 2025, 44(25):2025-2039. doi:10.1038/s41388-025-03371-7.
|
| [4] |
MONTICO B, GIURATO G, GUERRIERI R, et al. Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma[J]. J Exp Clin Cancer Res, 2025, 44:53. doi:10.1186/s13046-025-03289-8.
|
| [5] |
SHI T, LI X, ZHENG J, et al. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis[J]. Cell Oncol, 2023, 46(4):969-985. doi:10.1007/s13402-023-00791-z.
|
| [6] |
LIU Z, ZHANG Y, MA N, et al. Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma[J]. Cancer Cell, 2023, 41(11):1852-1870.e9. doi:10.1016/j.ccell.2023.09.011.
|
| [7] |
CHAKRABORTY S, NANDI P, MISHRA J, et al. Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation[J]. Cancer Lett, 2024, 587:216779. doi:10.1016/j.canlet.2024.216779.
|
| [8] |
YU Y S, KIM I S, BAEK S H. Decoding the dual role of autophagy in cancer through transcriptional and epigenetic regulation[J]. FEBS Lett, 2025, 599(16):2237-2249. doi:10.1002/1873-3468.70060.
|
| [9] |
JIA H, WEI J, ZHENG W, et al. The dual role of autophagy in cancer stem cells:implications for tumor progression and therapy resistance[J]. J Transl Med, 2025, 23:583. doi:10.1002/1873-3468.14999.
|
| [10] |
DEBNATH J, GAMMOH N, RYAN K M. Autophagy and autophagy-related pathways in cancer[J]. Nat Rev Mol Cell Biol, 2023, 24(8):560-575. doi:10.1038/s41580-023-00585-z.
|
| [11] |
HUANG X, ZHANG J, YAO J, et al. Phase separation of p62:roles and regulations in autophagy[J]. Trends Cell Biol, 2025, 35(10):992-1006. doi:10.1016/j.tcb.2025.03.003.
|
| [12] |
YANG S, HU C, CHEN X, et al. Crosstalk between metabolism and cell death in tumorigenesis[J]. Mol Cancer, 2024, 23:71. doi:10.1186/s12943-024-02018-5.
|
| [13] |
LI J, MA R, WANG X, et al. Sprouty genes regulate activated fibroblasts in mammary epithelial development and breast cancer[J]. Cell Death Dis, 2024, 15(4):256. doi:10.1038/s41419-024-06573-9.
|
| [14] |
NIU Z, WANG L, QIN X, et al. Macrophage derived miR-7219-3p-containing exosomes mediate fibroblast trans-differentiation by targeting SPRY1 in silicosis[J]. Toxicology, 2022, 479:153310. doi:10.1016/j.tox.2022.153310.
|
| [15] |
ZHAO G, PAN A Y, FENG Y, et al. Sprouty and Spred temporally regulate ERK1/2-signaling to suppress TGFβ-induced lens EMT[J]. Exp Eye Res, 2022, 219:109070. doi:10.1016/j.exer.2022.109070.
|
| [16] |
ZHANG M F, WAN S C, CHEN W B, et al. Transcription factor Dmrt1 triggers the SPRY1-NF-κB pathway to maintain testicular immune homeostasis and male fertility[J]. Zool Res, 2023, 44(3):505-521. doi:10.24272/j.issn.2095-8137.2023.202219.
|
| [17] |
FANG X, LU X, MA Y, et al. Possible involvement of a MEG3-miR-21-SPRY1-NF-κB feedback loop in spermatogenic cells proliferation,autophagy,and apoptosis[J]. iScience, 2024, 27(10):110904. doi:10.1016/j.isci.2024.110904.
|
| [18] |
LIU X, LAN Y, ZHANG D, et al. SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation[J]. Am J Cancer Res, 2014, 4(6):683-697.
|
| [19] |
CROCE C M, VAUX D, STRASSER A, et al. The BCL-2 protein family:from discovery to drug development[J]. Cell Death Differ, 2025, 32(8):1369-1381. doi:10.1038/s41418-025-01454-2.
|
| [20] |
LU Y, JIANG X, LI Y, et al. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia[J]. J Transl Med, 2024, 22:867. doi:10.1186/s12967-024-05377-3.
|
| [21] |
RUIZ-FERNÁNDEZ DE CÓRDOBA B, VALENCIA K, WELCH C, et al. Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer[J]. Signal Transduct Target Ther, 2025, 10:185. doi:10.1038/s41392-025-02114-0.
|
| [22] |
RINNERTHALER G, EGLE D, BARTSCH R, et al. Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer:the randomized phase 2 ABCSG-52/ATHENE trial[J]. Nat Cancer, 2025, 6(1):41-50. doi:10.1038/s43018-024-00809-7.
|